Glycated hemoglobin measurement and prediction of cardiovascular disease.

Autor:	Di Angelantonio E; University of Cambridge, Cambridge, United Kingdom., Gao P; University of Cambridge, Cambridge, United Kingdom., Khan H; University of Cambridge, Cambridge, United Kingdom., Butterworth AS; University of Cambridge, Cambridge, United Kingdom., Wormser D; University of Cambridge, Cambridge, United Kingdom., Kaptoge S; University of Cambridge, Cambridge, United Kingdom., Kondapally Seshasai SR; St George's University of London, London, United Kingdom., Thompson A; University of Cambridge, Cambridge, United Kingdom., Sarwar N; University of Cambridge, Cambridge, United Kingdom., Willeit P; University of Cambridge, Cambridge, United Kingdom., Ridker PM; Brigham and Women's Hospital, Boston, Massachusetts., Barr EL; Baker IDI Heart and Diabetes Institute, Victoria, Australia., Khaw KT; University of Cambridge, Cambridge, United Kingdom., Psaty BM; University of Washington, Seattle6Group Health Research Institute, Seattle, Washington., Brenner H; German Cancer Research Center, Heidelberg, Germany., Balkau B; Inserm, Villejuif, France9University Paris-Sud, Villejuif, France., Dekker JM; Vrije Universiteit Medical Center, Amsterdam, the Netherlands., Lawlor DA; University of Bristol, Bristol, United Kingdom., Daimon M; Yamagata University, Japan., Willeit J; Medical University Innsbruck, Austria., Njølstad I; University of Tromsø, Tromsø, Norway., Nissinen A; National Institute of Health and Welfare, Helsinki, Finland., Brunner EJ; University College London, London, United Kingdom., Kuller LH; University of Pittsburgh., Price JF; University of Edinburgh, Edinburgh, United Kingdom., Sundström J; Uppsala University, Uppsala, Sweden., Knuiman MW; University of Western Australia, Perth, Australia., Feskens EJ; Wageningen University, Wageningen, the Netherlands., Verschuren WM; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands., Wald N; Wolfson Institute of Preventive Medicine, London, United Kingdom., Bakker SJ; University of Groningen, University Medical Center Groningen, the Netherlands., Whincup PH; St George's University of London, London, United Kingdom., Ford I; University of Glasgow, Glasgow, United Kingdom., Goldbourt U; Sheba Medical Center, Tel Hashomer, Israel., Gómez-de-la-Cámara A; Hospital 12 de Octubre, Madrid, Spain., Gallacher J; Cardiff University, Cardiff, United Kingdom., Simons LA; University of New South Wales, Kensington, Australia., Rosengren A; Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Sutherland SE; Medical University of South Carolina, Charleston., Björkelund C; University of Gothenburg, Gothenburg, Sweden., Blazer DG; Duke University Medical Center, Durham, North Carolina., Wassertheil-Smoller S; Albert Einstein College of Medicine, New York, New York., Onat A; University of Istanbul, Istanbul, Turkey., Marín Ibañez A; San Jose Norte Health Centre, Zaragoza, Spain., Casiglia E; University of Padova, Padova, Italy., Jukema JW; Leiden University Medical Center, Leiden, the Netherlands., Simpson LM; University of Texas School of Public Health, Houston., Giampaoli S; Istituto Superiore di Sanità, Rome, Italy., Nordestgaard BG; Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark., Selmer R; Norwegian Institute of Public Health, Oslo, Norway., Wennberg P; Umeå University, Umeå, Sweden., Kauhanen J; University of Eastern Finland, Kuopio, Finland., Salonen JT; University of Helsinki, Helsinki, Finland., Dankner R; The Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer, Israel47Tel Aviv University, Tel Aviv, Israel48The Feinstein Institute for Medical Research, New York, New York., Barrett-Connor E; University of California, San Diego., Kavousi M; Erasmus Medical Center, Rotterdam, the Netherlands., Gudnason V; Icelandic Heart Association, Reyjavik, Iceland52University of Iceland, Reykjavik, Iceland., Evans D; Rush University Medical Center, Chicago, Illinois., Wallace RB; University of Iowa College of Public Health, Iowa City., Cushman M; University of Vermont, Burlington., D'Agostino RB Sr; Boston University, Boston, Massachusetts., Umans JG; Georgetown University Medical Centre, Washington, DC., Kiyohara Y; Kyushu University, Kyushu, Japan., Nakagawa H; Kanazawa Medical University, Ishikawa, Japan., Sato S; Osaka Medical Center for Health Science and Promotion/Chiba Prefectural Institute of Public Health, Osaka, Japan., Gillum RF; Howard University, Washington, DC., Folsom AR; University of Minnesota, Minneapolis., van der Schouw YT; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Moons KG; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Griffin SJ; University of Cambridge, Cambridge, United Kingdom., Sattar N; University of Glasgow, Glasgow, United Kingdom., Wareham NJ; University of Cambridge, Cambridge, United Kingdom., Selvin E; Johns Hopkins University, Baltimore, Maryland., Thompson SG; University of Cambridge, Cambridge, United Kingdom., Danesh J; University of Cambridge, Cambridge, United Kingdom.
Jazyk:	angličtina
Zdroj:	JAMA [JAMA] 2014 Mar 26; Vol. 311 (12), pp. 1225-33.
DOI:	10.1001/jama.2014.1873
Abstrakt:	Importance: The value of measuring levels of glycated hemoglobin (HbA1c) for the prediction of first cardiovascular events is uncertain. Objective: To determine whether adding information on HbA1c values to conventional cardiovascular risk factors is associated with improvement in prediction of cardiovascular disease (CVD) risk. Design, Setting, and Participants: Analysis of individual-participant data available from 73 prospective studies involving 294,998 participants without a known history of diabetes mellitus or CVD at the baseline assessment. Main Outcomes and Measures: Measures of risk discrimination for CVD outcomes (eg, C-index) and reclassification (eg, net reclassification improvement) of participants across predicted 10-year risk categories of low (<5%), intermediate (5% to <7.5%), and high (≥ 7.5%) risk. Results: During a median follow-up of 9.9 (interquartile range, 7.6-13.2) years, 20,840 incident fatal and nonfatal CVD outcomes (13,237 coronary heart disease and 7603 stroke outcomes) were recorded. In analyses adjusted for several conventional cardiovascular risk factors, there was an approximately J-shaped association between HbA1c values and CVD risk. The association between HbA1c values and CVD risk changed only slightly after adjustment for total cholesterol and triglyceride concentrations or estimated glomerular filtration rate, but this association attenuated somewhat after adjustment for concentrations of high-density lipoprotein cholesterol and C-reactive protein. The C-index for a CVD risk prediction model containing conventional cardiovascular risk factors alone was 0.7434 (95% CI, 0.7350 to 0.7517). The addition of information on HbA1c was associated with a C-index change of 0.0018 (0.0003 to 0.0033) and a net reclassification improvement of 0.42 (-0.63 to 1.48) for the categories of predicted 10-year CVD risk. The improvement provided by HbA1c assessment in prediction of CVD risk was equal to or better than estimated improvements for measurement of fasting, random, or postload plasma glucose levels. Conclusions and Relevance: In a study of individuals without known CVD or diabetes, additional assessment of HbA1c values in the context of CVD risk assessment provided little incremental benefit for prediction of CVD risk.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu